Literature DB >> 2765367

Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia.

J M Sargent1, C G Taylor.   

Abstract

We describe the application of a simple, rapid, semi-automated assay to the sensitivity testing of cytotoxic drugs in 23 patients with acute myeloid leukaemia (AML). The survival of blast cells from the bone marrow was measured by the MTT assay after 48 h continuous exposure to drugs both singly and in combination. There was a linear relationship between the number of leukaemic cells and the optical density of the formazan produced. The assay demonstrated a variation in drug sensitivity between patients. The technique was reproducible and there was no significant difference in response between blast cells obtained from bone marrow or from peripheral blood. Preliminary results show a correlation between in vitro and in vivo data. The test can be repeated throughout the course of the disease to help identify any change in tumour sensitivity. This technique appears to give useful information to assist in the management of acute myeloid leukaemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765367      PMCID: PMC2247032          DOI: 10.1038/bjc.1989.252

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay.

Authors:  P R Twentyman; N E Fox; J K Rees
Journal:  Br J Haematol       Date:  1989-01       Impact factor: 6.998

2.  Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

Authors:  L M Weisenthal; P L Dill; J Z Finklestein; T E Duarte; J A Baker; E M Moran
Journal:  Cancer Treat Rep       Date:  1986-11

3.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

Authors:  J Carmichael; W G DeGraff; A F Gazdar; J D Minna; J B Mitchell
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

4.  Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia.

Authors:  A Raza; Y Maheshwari; N Mandava; Z Yasin; S Perveen; G Mayers; G Browman; J Goldberg; A Gottlieb; H Grunwald
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

5.  Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity.

Authors:  L M Weisenthal; P L Dill; N B Kurnick; M E Lippman
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

Review 6.  Clonogenic and nonclonogenic in vitro chemosensitivity assays.

Authors:  L M Weisenthal; M E Lippman
Journal:  Cancer Treat Rep       Date:  1985-06

7.  Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro.

Authors:  J D Schwarzmeier; E Paietta; K Mittermayer; R Pirker
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

8.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.

Authors:  F Denizot; R Lang
Journal:  J Immunol Methods       Date:  1986-05-22       Impact factor: 2.303

9.  Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.

Authors:  J K Rees; R G Gray; D Swirsky; F G Hayhoe
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

10.  The influence of sample source and cell concentration on the in vitro chemosensitivity of haematological tumours.

Authors:  M C Bird; S Forskitt; E D Gilby; A G Bosanquet
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

View more
  45 in total

1.  Preparation, safety, pharmacokinetics, and pharmacodynamics of liposomes containing Brucea javanica oil.

Authors:  Yanxia Cui; Zimei Wu; Xiaoxu Liu; Rui Ni; Xuanxuan Zhu; Lulu Ma; Jianping Liu
Journal:  AAPS PharmSciTech       Date:  2010-05-19       Impact factor: 3.246

2.  Chemotherapy in experimental brain tumor, part 1: in vitro colorimetric MTT assay.

Authors:  C M Hand; J R Vender; P Black
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

3.  New cholestane glycosides and sterols from the underground parts of Chamaelirium luteum and their cytotoxic activity.

Authors:  Akihito Yokosuka; Kenichi Takagi; Yoshihiro Mimaki
Journal:  J Nat Med       Date:  2012-11-16       Impact factor: 2.343

4.  Antimicrobial activity and stability of electron beam irradiated dental irrigants.

Authors:  A Veena Shetty; A Geethashri; K J Palaksha; K R Sridhar; Ganesh Sanjeev
Journal:  J Clin Diagn Res       Date:  2014-11-20

5.  Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity.

Authors:  Y Maehara; Y Sakaguchi; Y Emi; T Kusumoto; S Kohnoe; M Mori; K Sugimachi
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

6.  Pristimerin Inhibits LPS-Triggered Neurotoxicity in BV-2 Microglia Cells Through Modulating IRAK1/TRAF6/TAK1-Mediated NF-κB and AP-1 Signaling Pathways In Vitro.

Authors:  Bin Hui; Liping Zhang; Qinhua Zhou; Ling Hui
Journal:  Neurotox Res       Date:  2017-11-08       Impact factor: 3.911

7.  Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay.

Authors:  J P Jordan; C M Hand; R S Markowitz; P Black
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

8.  Influence of paeonol on expression of COX-2 and p27 in HT-29 cells.

Authors:  Jun-Mei Ye; Tao Deng; Jian-Bao Zhang
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

9.  Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine.

Authors:  M Haber; J Madafiglio; M D Norris
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 10.  Prediction of response to drug therapy of cancer. A review of in vitro assays.

Authors:  W T Bellamy
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.